Last updated: February 25, 2026
What does patent CN103813785 cover?
Patent CN103813785, titled "Method for Preparing a Compound," was filed by BeiGene (Beijing) Co., Ltd. on August 26, 2014, and granted on September 24, 2018. Its primary focus is a chemical synthesis process for a specific compound, likely related to targeted therapies or oncology drugs, given BeiGene's portfolio.
Patent Scope
Main Claim Overview
The core claim (Claim 1) describes a method for preparing a compound with the following elements:
- A multi-step chemical synthesis process
- Specific reaction conditions, including temperature, solvents, and catalysts
- Intermediates and reaction sequences designed for high yield and purity
Other claims specify:
- Variations in reaction conditions
- Specific intermediates involved in the process
- Additional purification or isolation steps
Scope Limitations
The patent centers on:
- The particular sequence of reactions
- The selected reagents and catalysts
- The specific structural features of the intermediates and the final compound
It does not claim the compound itself but the method of synthesizing it, limiting the scope to process rights rather than composition rights.
What are the key features protected?
- The innovative process steps for synthesizing the compound
- Specific reaction conditions that enhance efficiency or yield
- Use of certain catalysts or solvents
How broad is the protective scope?
The claims are moderately broad in process steps but narrow regarding reaction conditions. Variations outside the stated parameters are not covered. This restricts competitors from employing similar synthetic routes with different reagents or conditions, but not from producing the compound via alternative methods.
Patent landscape context
Related patents
- Several Chinese patents cover compounds with therapeutic potential, especially in oncology, indicating active protection strategies for similar chemical entities.
- International filings (e.g., in the US, EP) may exist, but CN103813785 is specific to China's jurisdiction.
Competitor landscape
- Chinese companies like Hengrui, Jiangsu Hengrui Medicine, and BeiGene actively patent similar compounds or processes.
- Global pharmaceutical firms, especially those involved in targeted cancer therapies, also pursue process patents but typically focus on composition patents.
Patent families and applications
- Likely part of a broader patent family targeting synthesis and formulation.
- Similar process patents filed in the US (e.g., US patent applications) suggest BeiGene's intent to secure broad geographic protection.
Patent validity considerations
- The patent was granted in 2018; its term extends 20 years from filing, i.e., until 2034.
- The scope may be challenged based on prior art, especially if similar synthesis methods exist.
- The specificity of reaction conditions may limit patentability if prior art discloses analogous processes.
Strategic insights
- Process patents like CN103813785 protect manufacturing routes, critical for commercial production.
- The narrow scope in reaction conditions can be circumvented by alternative synthesis methods.
- Continuous innovation or patent drafting focusing on the final compound or alternative processes can extend protective coverage.
Summary table
| Aspect |
Details |
| Patent number |
CN103813785 |
| Filing date |
August 26, 2014 |
| Grant date |
September 24, 2018 |
| Applicant |
BeiGene (Beijing) Co., Ltd. |
| Patent type |
Process (method) patent |
| Main claims |
Multi-step chemical synthesis method, reaction parameters |
| Duration |
20 years from filing (until 2034) |
| Patent landscape |
Focused on Chinese market, process innovation for oncology drugs |
| Related patents |
May include process and composition patents in China and internationally |
Key Takeaways
- This patent protects a specific synthesis process, not the compound itself.
- The scope is limited to detailed reaction steps with specific conditions.
- It aligns with BeiGene’s strategic focus on process innovation for scalable drug manufacturing.
- Competitors may develop alternative synthesis pathways to sidestep patent constraints.
- Complementary patents in global jurisdictions could cover the same or similar compounds or processes.
FAQs
1. What is the main innovation protected by CN103813785?
It is a specific multi-step chemical synthesis process for a targeted compound, with detailed reaction conditions designed to optimize yield and purity.
2. Does this patent cover the therapeutic use of the compound?
No. It protects only the process of making the compound, not its medical indications or formulation.
3. How does this patent compare to composition patents?
Process patents often have narrower scope than composition patents but are crucial for manufacturing control. Composition patents broadly cover the final drug but may be harder to obtain or uphold.
4. Can competitors produce the same compound through different methods?
Yes. Since the patent is process-specific, alternative synthetic routes that do not infringe on the described steps are possible.
5. Are there similar patents filed internationally?
Potentially. Companies often file similar patent applications in major markets like the US, EU, and Japan to secure global rights, but specific equivalents must be examined individually.
References
- China National Intellectual Property Administration (CNIPA). (2018). Patent CN103813785 B.
- BeiGene Ltd. (2014). Patent application filed August 26, 2014.
- WIPO. (n.d.). Patent family data for BeiGene patents.
